CSPC Pharmaceutical Group Limited
Other OTCTotal Valuation
CSPC Pharmaceutical Group Limited carries a market capitalization of 10.38B, placing it among publicly traded companies globally. Its enterprise value stands at 63.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.38B |
| Enterprise Value | 63.18B |
Share Statistics
CSPC Pharmaceutical Group Limited currently has 11.76B shares outstanding.
| Shares Outstanding | 11.76B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
CSPC Pharmaceutical Group Limited trades at a trailing price-to-earnings ratio of 24.76. The price-to-sales ratio is 4.68, and the price-to-book ratio stands at 2.00.
| PE Ratio | 24.76 |
| PS Ratio | 4.68 |
| PB Ratio | 2.00 |
| P/TBV Ratio | 2.12 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, CSPC Pharmaceutical Group Limited trades at an EV/EBITDA multiple of 17.68 and an EV/FCF ratio of 5,121.41. The EV/Sales ratio of 4.11 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.68 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.11 |
| EV / EBITDA | 17.68 |
| EV / EBIT | 17.68 |
| EV / FCF | 5,121.41 |
Financial Position
CSPC Pharmaceutical Group Limited maintains a current ratio of 2.54, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.07, indicating moderate leverage, while an interest coverage ratio of 235.55 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.54 |
| Quick Ratio | 1.03 |
| Debt / Equity | 1.07 |
| Debt / EBITDA | 0.11 |
| Interest Coverage | 235.55 |
Financial Efficiency
CSPC Pharmaceutical Group Limited posts a return on equity of 8.33 and a return on invested capital of 8.16.
| Return on Equity (ROE) | 8.33 |
| Return on Assets (ROA) | 6.35 |
| Return on Invested Capital (ROIC) | 8.16 |
| Return on Capital Employed (ROCE) | 7.60 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.47 |
Taxes
Over the trailing twelve months, CSPC Pharmaceutical Group Limited has paid 693.17M in income taxes, reflecting an effective tax rate of 18.69.
| Income Tax | 693.17M |
| Effective Tax Rate | 18.69 |
Stock Price Statistics
CSPC Pharmaceutical Group Limited's stock has declined approximately -3.95778% over the past 52 weeks. The 50-day moving average sits at 4.31, while the 200-day moving average is 4.57.
| Beta (5Y) | N/A |
| 52-Week Price Change | -3.95778% |
| 50-Day Moving Average | 4.31 |
| 200-Day Moving Average | 4.57 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CSPC Pharmaceutical Group Limited generated 15.37B in revenue and converted that into 2.91B in net income, yielding earnings per share of 1.02. EBITDA reached 3.57B, while operating income came in at 3.57B.
| Revenue | 15.37B |
| Gross Profit | 10.94B |
| Operating Income | 3.57B |
| Pretax Income | 3.71B |
| Net Income | 2.91B |
| EBITDA | 3.57B |
| EBIT | 3.57B |
| Earnings Per Share (EPS) | 1.02 |
Balance Sheet
CSPC Pharmaceutical Group Limited holds 10.79B in cash and equivalents against 388.87M in total debt, resulting in a net debt position of -8.15B. Total book value stands at 36.04B, with working capital of 16.03B providing operational flexibility.
| Cash & Cash Equivalents | 10.79B |
| Total Debt | 388.87M |
| Net Debt | -8.15B |
| Equity (Book Value) | 36.04B |
| Book Value Per Share | 12.16 |
| Working Capital | 16.03B |
Margins
CSPC Pharmaceutical Group Limited operates with a gross margin of 71.17, reflecting its pricing power and cost economics. The operating margin of 23.25 and net profit margin of 18.91 provide insight into operational efficiency.
| Gross Margin | 71.17 |
| Operating Margin | 23.25 |
| Pretax Margin | 24.12 |
| Profit Margin | 18.91 |
| EBITDA Margin | 23.25 |
Stock Splits
CSPC Pharmaceutical Group Limited's most recent stock split took place on December 10, 2020 with a 5:8 split ratio.
| Last Split Date | 12/10/2020 |
| Split Ratio | 5:8 |
Scores
CSPC Pharmaceutical Group Limited posts an Altman Z-Score of 5.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.57 |